mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however,...

Full description

Saved in:
Bibliographic Details
Published in:Military medical research 2022-07, Vol.9 (1), p.40-40, Article 40
Main Authors: Tang, Tian-Yu, Huang, Xing, Zhang, Gang, Lu, Ming-Hao, Liang, Ting-Bo
Format: Article
Language:English
Subjects:
Antigens
Bile Duct Neoplasms
Bile Ducts, Intrahepatic
Bioinformatics
Cancer therapies
Cholangiocarcinoma
Cholangiocarcinoma (CHOL)
Gene expression
Genomes
Genomics
Growth factors
Humans
Immune microenvironment
Immune subtype
Immune system
Immunotherapy
Kinases
Medical prognosis
mRNA vaccine
mRNA Vaccines
Mutation
Peptides
Response rates
RNA, Messenger
Tumor antigen
Tumors
Vaccines, Synthetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.
ISSN:2054-9369
2095-7467
2054-9369
DOI:10.1186/s40779-022-00399-8